{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:10:01Z","timestamp":1783537801569,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"DOI":"10.1007\/s11882-025-01245-2","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:32:59Z","timestamp":1771219979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting Mast Cells in Chronic Spontaneous Urticaria"],"prefix":"10.1007","volume":"26","author":[{"given":"Nikkia","family":"Zarabian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Stines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"4","key":"1245_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.anai.2024.04.023","volume":"133","author":"I Puxeddu","year":"2024","unstructured":"Puxeddu I, Pistone F, Pisani F, Levi-Schaffer F. Mast cell signaling and its role in urticaria. Ann Allergy Asthma Immunol. 2024;133(4):374\u20139. https:\/\/doi.org\/10.1016\/j.anai.2024.04.023.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"1245_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.alit.2023.05.003","volume":"72","author":"D Elieh-Ali-Komi","year":"2023","unstructured":"Elieh-Ali-Komi D, Metz M, Kolkhir P, et al. Chronic urticaria and the pathogenic role of mast cells. Allergol Int. 2023;72(4):359\u201368. https:\/\/doi.org\/10.1016\/j.alit.2023.05.003.","journal-title":"Allergol Int"},{"issue":"1","key":"1245_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00389-z","volume":"8","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Gim\u00e9nez-Arnau AM, Kulthanan K, et al. Urticaria. Nat Rev Dis Primers. 2022;8(1):61. https:\/\/doi.org\/10.1038\/s41572-022-00389-z.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"1245_CR4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s13555-024-01173-5","volume":"14","author":"A Friedman","year":"2024","unstructured":"Friedman A, Kwatra SG, Yosipovitch G. A practical approach to diagnosing and managing chronic spontaneous urticaria. Dermatol Ther (Heidelb). 2024;14(6):1371\u201387. https:\/\/doi.org\/10.1007\/s13555-024-01173-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1245_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40265-025-02170-4","volume":"85","author":"P Kolkhir","year":"2025","unstructured":"Kolkhir P, Fok JS, Kocat\u00fcrk E, et al. Update on the treatment of chronic spontaneous urticaria. Drugs. 2025;85(4):475\u201386. https:\/\/doi.org\/10.1007\/s40265-025-02170-4.","journal-title":"Drugs"},{"key":"1245_CR6","doi-asserted-by":"publisher","unstructured":"Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean?\u00a0J Invest Dermatol. 2015;8(12). https:\/\/doi.org\/10.1111\/j.0022202X.2005.23621.x","DOI":"10.1111\/j.0022202X.2005.23621.x"},{"issue":"3","key":"1245_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.anai.2024.12.008","volume":"134","author":"W Soong","year":"2025","unstructured":"Soong W, Patil D, Rodrigues J, et al. Clinical profile, prevalence, and burden of chronic spontaneous urticaria in the United States. Ann Allergy Asthma Immunol. 2025;134(3):324-332.e4. https:\/\/doi.org\/10.1016\/j.anai.2024.12.008.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"1245_CR8","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734\u201366. https:\/\/doi.org\/10.1111\/all.15090.","journal-title":"Allergy"},{"issue":"3","key":"1245_CR9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s40629-023-00272-7","volume":"32","author":"S Melchers","year":"2023","unstructured":"Melchers S, Nicolay JP. Chronic spontaneous urticaria\u2014status quo and future. Allergo J Int. 2023;32(3):326\u201336. https:\/\/doi.org\/10.1007\/s40629-023-00272-7.","journal-title":"Allergo J Int"},{"issue":"7","key":"1245_CR10","doi-asserted-by":"publisher","first-page":"101068","DOI":"10.1016\/j.waojou.2025.101068","volume":"18","author":"JA Bernstein","year":"2025","unstructured":"Bernstein JA, Ansotegui I, Asero R, et al. Diagnostic testing for chronic spontaneous urticaria with or without angioedema: the do\u2019s, don\u2019ts and maybe\u2019s. World Allergy Organ J. 2025;18(7):101068. https:\/\/doi.org\/10.1016\/j.waojou.2025.101068.","journal-title":"World Allergy Organ J"},{"issue":"5","key":"1245_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15050608","volume":"15","author":"Z Golu\u0161in","year":"2025","unstructured":"Golu\u0161in Z, Maletin N, Denda N, Ni\u0161avi\u0107 M, Radovanovi\u0107 B, Nikoli\u0107 O. Autoimmune thyroid diseases in chronic spontaneous urticaria: the role of hormones, anti-thyroid antibodies, and ultrasound. Diagnostics. 2025;15(5):608. https:\/\/doi.org\/10.3390\/diagnostics15050608.","journal-title":"Diagnostics"},{"issue":"5","key":"1245_CR12","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jaci.2023.03.034","volume":"152","author":"T Buttgereit","year":"2023","unstructured":"Buttgereit T, Salameh P, Sydorenko O, et al. The 7-day recall period version of the Urticaria Control Test\u2014UCT7. J Allergy Clin Immunol. 2023;152(5):1210-1217.e14. https:\/\/doi.org\/10.1016\/j.jaci.2023.03.034.","journal-title":"J Allergy Clin Immunol"},{"issue":"13","key":"1245_CR13","doi-asserted-by":"publisher","first-page":"10679","DOI":"10.3390\/ijms241310679","volume":"24","author":"D Ribatti","year":"2023","unstructured":"Ribatti D, d\u2019Amati A. Hematopoiesis and mast cell development. Int J Mol Sci. 2023;24(13):10679. https:\/\/doi.org\/10.3390\/ijms241310679.","journal-title":"Int J Mol Sci"},{"key":"1245_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.coi.2021.03.015","volume":"72","author":"U Blank","year":"2021","unstructured":"Blank U, Huang H, Kawakami T. The high affinity IgE receptor: a signaling update. Curr Opin Immunol. 2021;72:51\u20138. https:\/\/doi.org\/10.1016\/j.coi.2021.03.015.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"1245_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4168\/aair.2021.13.2.206","volume":"13","author":"S Altrichter","year":"2021","unstructured":"Altrichter S, Fok JS, Jiao Q, Kolkhir P, Pyatilova P, Romero SM, et al. Total IgE as a marker for chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2021;13(2):206\u201318. https:\/\/doi.org\/10.4168\/aair.2021.13.2.206.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"8","key":"1245_CR16","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s13555-023-00955-7","volume":"13","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Soong W, Bernstein JA. Chronic spontaneous urticaria: how to measure it and the need to define treatment success. Dermatol Ther (Heidelb). 2023;13(8):1629\u201346. https:\/\/doi.org\/10.1007\/s13555-023-00955-7.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1245_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jaci.2022.04.010","volume":"150","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Mu\u00f1oz M, Asero R, Metz M, Xiang YK, Maurer M. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;150(1):119\u201331. https:\/\/doi.org\/10.1016\/j.jaci.2022.04.010.","journal-title":"J Allergy Clin Immunol"},{"key":"1245_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.657211","volume":"12","author":"M Sauer","year":"2021","unstructured":"Sauer M, Scheffel J, Frischbutter S, Kolkhir P, Xiang YK, Siebenhaar F, et al. Lower IgA levels in chronic spontaneous urticaria are associated with lower IgE levels and autoimmunity. Front Immunol. 2021;12:657211. https:\/\/doi.org\/10.3389\/fimmu.2021.657211.","journal-title":"Front Immunol"},{"issue":"6","key":"1245_CR19","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jaci.2022.08.022","volume":"150","author":"M Hide","year":"2022","unstructured":"Hide M, Kaplan AP. Concise update on the pathogenesis of chronic spontaneous urticaria (CSU). J Allergy Clin Immunol. 2022;150(6):1403\u20134. https:\/\/doi.org\/10.1016\/j.jaci.2022.08.022.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1245_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaci.2025.04.004","volume":"156","author":"D Wong","year":"2025","unstructured":"Wong D, Waserman S, Sussman GL. Endotypes of chronic spontaneous urticaria and angioedema. J Allergy Clin Immunol. 2025;156(1):17\u201323. https:\/\/doi.org\/10.1016\/j.jaci.2025.04.004.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1245_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/14656566.2024.2345731","volume":"25","author":"YK Xiang","year":"2024","unstructured":"Xiang YK, Fok JS, Podder I, et al. An update on the use of antihistamines in managing chronic urticaria. Expert Opin Pharmacother. 2024;25(5):551\u201369. https:\/\/doi.org\/10.1080\/14656566.2024.2345731.","journal-title":"Expert Opin Pharmacother"},{"key":"1245_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109198","volume":"112","author":"S Ayse Ornek","year":"2022","unstructured":"Ayse Ornek S, Orcen C, Church MK, Kocaturk E. An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria. Int Immunopharmacol. 2022;112:109198. https:\/\/doi.org\/10.1016\/j.intimp.2022.109198.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"1245_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.anai.2024.05.020","volume":"133","author":"TK Min","year":"2024","unstructured":"Min TK, Saini SS. The future of targeted therapy in chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2024;133(6):637\u201343. https:\/\/doi.org\/10.1016\/j.anai.2024.05.020.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"1245_CR24","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s13555-023-01040-9","volume":"13","author":"TB Casale","year":"2023","unstructured":"Casale TB, Gimenez-Arnau AM, Bernstein JA, et al. Omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status. Dermatol Ther (Heidelb). 2023;13(11):2573\u201388. https:\/\/doi.org\/10.1007\/s13555-023-01040-9.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1245_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/all.13083","volume":"72","author":"AP Kaplan","year":"2017","unstructured":"Kaplan AP, Gim\u00e9nez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72(4):519\u201333. https:\/\/doi.org\/10.1111\/all.13083.","journal-title":"Allergy"},{"key":"1245_CR26","unstructured":"Novartis AG. XOLAIR\u00ae (omalizumab) summary of product characteristics.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xolair-epar-product-information_en.pdf. Accessed November 9, 2023."},{"issue":"12","key":"1245_CR27","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1111\/all.14033","volume":"74","author":"R Erta\u015f","year":"2019","unstructured":"Erta\u015f R, Hawro T, Altrichter S, et al. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU. Allergy. 2019;74(12):2395\u20138. https:\/\/doi.org\/10.1111\/all.14033.","journal-title":"Allergy"},{"issue":"4","key":"1245_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40629-020-00126-6","volume":"29","author":"A G\u00fclsen","year":"2020","unstructured":"G\u00fclsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J Int. 2020;29(4):97\u2013125. https:\/\/doi.org\/10.1007\/s40629-020-00126-6.","journal-title":"Allergo J Int"},{"key":"1245_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-023-00820-4","volume":"19","author":"AF LaCava","year":"2023","unstructured":"LaCava AF, Fadugba OO. Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases. Allergy Asthma Clin Immunol. 2023;19:78. https:\/\/doi.org\/10.1186\/s13223-023-00820-4.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1245_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5243825","volume":"2022","author":"H-L Chiang","year":"2022","unstructured":"Chiang H-L, Chen C-H, Koo M, et al. Predictors of response to oral medications and low-histamine diet in patients with chronic urticaria. J Immunol Res. 2022;2022:5243825. https:\/\/doi.org\/10.1155\/2022\/5243825.","journal-title":"J Immunol Res"},{"issue":"10450","key":"1245_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(24)00852-3","volume":"404","author":"T Zuberbier","year":"2024","unstructured":"Zuberbier T, Ensina LF, Gim\u00e9nez-Arnau A, et al. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment. Lancet. 2024;404(10450):393\u2013404. https:\/\/doi.org\/10.1016\/S0140-6736(24)00852-3.","journal-title":"Lancet"},{"key":"1245_CR32","unstructured":"Sanofi. Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria [press release]. April 18, 2025. Accessed July 25, 2025.\u00a0https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2025\/2025-04-18-15-15-00-3064131"},{"issue":"5","key":"1245_CR33","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc'h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204. https:\/\/doi.org\/10.1111\/all.14151.","journal-title":"Allergy"},{"key":"1245_CR34","doi-asserted-by":"publisher","unstructured":"Maurer M, Casale TB, Saini SS, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials.\u00a0J Allergy Clin Immunol. 2024;S0091-6749(24)00196-91https:\/\/doi.org\/10.1016\/j.jaci.2024.01.028","DOI":"10.1016\/j.jaci.2024.01.028"},{"key":"1245_CR35","doi-asserted-by":"publisher","unstructured":"Jan M, Qazi K, Noor A, et al. A new era in chronic spontaneous urticaria: FDA\u00a0approval of the oral BTK inhibitor remibrutinib. Ann Med Surg. 2026;88(1):974\u2013975. https:\/\/doi.org\/10.1097\/MS9.0000000000004298.","DOI":"10.1097\/MS9.0000000000004298"},{"issue":"2","key":"1245_CR36","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jaci.2022.08.027","volume":"151","author":"M Maurer","year":"2023","unstructured":"Maurer M, Berger W, Gim\u00e9nez-Arnau A, Hayama K, Jain V, Reich A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol. 2023;151(2):446\u201354. https:\/\/doi.org\/10.1016\/j.jaci.2022.08.027.","journal-title":"J Allergy Clin Immunol"},{"issue":"10422","key":"1245_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","volume":"403","author":"M Maurer","year":"2024","unstructured":"Maurer M, Ensina LF, Gimenez-Arnau AM, et al. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Lancet. 2024;403(10422):147\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(23)01684-7.","journal-title":"Lancet"},{"issue":"4","key":"1245_CR38","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4103\/ijd.ijd_1085_23","volume":"69","author":"A De","year":"2024","unstructured":"De A, Pal S, Singh S, et al. An open-label, investigator-initiated, single-centre pilot study to determine the safety and efficacy of tofacitinib in resistant chronic spontaneous urticaria. Indian J Dermatol. 2024;69(4):312\u20136. https:\/\/doi.org\/10.4103\/ijd.ijd_1085_23.","journal-title":"Indian J Dermatol"},{"issue":"3","key":"1245_CR39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/jdv.20541","volume":"39","author":"M Metz","year":"2025","unstructured":"Metz M. No allergy, but mast cells are involved: MRGPRX2 in chronic inflammatory skin diseases. J Eur Acad Dermatol Venereol. 2025;39(3):451\u20132. https:\/\/doi.org\/10.1111\/jdv.20541.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1245_CR40","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/cea.13616","volume":"50","author":"DA Sabag","year":"2020","unstructured":"Sabag DA, Matanes L, Bejar J, et al. Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin Exp Allergy. 2020;50(7):799\u2013804. https:\/\/doi.org\/10.1111\/cea.13616.","journal-title":"Clin Exp Allergy"},{"issue":"14","key":"1245_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147598","volume":"25","author":"K Gomu\u0142ka","year":"2024","unstructured":"Gomu\u0142ka K, Tota M, Laska J, et al. Serum concentration of IL-5 receptor (IL-5R) and associations with disease severity in patients with chronic spontaneous urticaria (CSU) and atopic dermatitis (AD). Int J Mol Sci. 2024;25(14):7598. https:\/\/doi.org\/10.3390\/ijms25147598.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1245_CR42","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.jaci.2025.01.045","volume":"155","author":"J McLaren","year":"2025","unstructured":"McLaren J, Chon Y, Gorski KS, et al. Tezepelumab for the treatment of chronic spontaneous urticaria: results of the phase 2b INCEPTION study. J Allergy Clin Immunol. 2025;155(6):1945\u201356. https:\/\/doi.org\/10.1016\/j.jaci.2025.01.045.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1245_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/all.15850","volume":"79","author":"M Metz","year":"2023","unstructured":"Metz M, Kolkhir P, Altrichter S, et al. Mast cell silencing: a novel therapeutic approach for urticaria and other mast cell-mediated diseases. Allergy. 2023;79(1):37\u201351. https:\/\/doi.org\/10.1111\/all.15850.","journal-title":"Allergy"},{"issue":"4","key":"1245_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041602","volume":"22","author":"K Kotwica-Mojzych","year":"2021","unstructured":"Kotwica-Mojzych K, Jod\u0142owska-J\u0119drych B, Mojzych M. CD200:CD200R interactions and their importance in immunoregulation. Int J Mol Sci. 2021;22(4):1602. https:\/\/doi.org\/10.3390\/ijms22041602.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1245_CR45","doi-asserted-by":"publisher","first-page":"671","DOI":"10.33549\/physiolres.934710","volume":"70","author":"P Sun","year":"2021","unstructured":"Sun P, Li R, Meng Y, et al. Introduction to DOK2 and its potential role in cancer. Physiol Res. 2021;70(5):671\u201385. https:\/\/doi.org\/10.33549\/physiolres.934710.","journal-title":"Physiol Res"},{"key":"1245_CR46","unstructured":"Eli Lilly and Company. A phase 2 study to evaluate LY3454738 in adults with chronic spontaneous urticaria inadequately controlled with H1-antihistamines.\u00a0ClinicalTrials.gov Identifier: NCT04159701. Updated February 14, 2022. Accessed July 25, 2025.\u00a0https:\/\/clinicaltrials.gov\/study\/NCT04159701?tab=results"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-025-01245-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-025-01245-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-025-01245-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:06:29Z","timestamp":1771430789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-025-01245-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1245"],"URL":"https:\/\/doi.org\/10.1007\/s11882-025-01245-2","relation":{},"ISSN":["1534-6315"],"issn-type":[{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Friedman is a consultant and speaker for Regeneron and Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}